The role of matrix metalloproteinases in colorectal cancer

Cancers

Volumn 6, Issue 1, 2014, Pages 366-375

  Said, Anan H ^a   Raufman, Jean Pierre ^a   Xie, Guofeng ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Matrix metalloproteinase inhibitors (MMPIs); Matrix metalloproteinases (MMPs); Tissue inhibitors of metalloproteinases (TIMPs)

Indexed keywords

EID: 84893943734     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6010366     Document Type: Review

References (49)

1. Surveillance, Epidemiology, and End Results (SEER) Program. Stat Fact Sheets: Colon and Rectum Cancer. Available online: http://seer.Cancer.Gov/statfacts/html/colorect.Html/ (accessed on 25 October 2013).
2. Howlader, N.; Noone, A.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Altekruse, S.; Kosary, C.; Ruhl, J.; Tatalovich, Z.; et al. SEER Cancer Statistics Review, 1975-2008; National Cancer Institute: Bethesda, MD, USA, 2011.
3. Hua, H.; Li, M.; Luo, T.; Yin, Y.; Jiang, Y. Matrix metalloproteinases in tumorigenesis: An evolving paradigm. Cell. Mol. Life Sci. 2011, 68, 3853-3868.
4. Van der Jagt, M.F.; Wobbes, T.; Strobbe, L.J.; Sweep, F.C.; Span, P.N. Metalloproteinases and their regulators in colorectal cancer. J. Surg. Oncol. 2010, 101, 259-269.
5. Hu, J.; van den Steen, P.E.; Sang, Q.X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 2007, 6, 480-498.
6. Sunami, E.; Tsuno, N.; Osada, T.; Saito, S.; Kitayama, J.; Tomozawa, S.; Tsuruo, T.; Shibata, Y.; Muto, T.; Nagawa, H. Mmp-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000, 5, 108-114.
7. Shiozawa, J.; Ito, M.; Nakayama, T.; Nakashima, M.; Kohno, S.; Sekine, I. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod. Pathol. 2000, 13, 925-933.
8. Bendardaf, R.; Buhmeida, A.; Ristamaki, R.; Syrjanen, K.; Pyrhonen, S. Mmp-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand. J. Gastroenterol. 2007, 42, 1473-1478.
9. Kim, M.Y.; Oskarsson, T.; Acharyya, S.; Nguyen, D.X.; Zhang, X.H.; Norton, L.; Massague, J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139, 1315-1326.
10. Xie, G.; Cheng, K.; Shant, J.; Raufman, J.P. Acetylcholine-induced activation of m3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296, G755-G763.
11. Raufman, J.P.; Cheng, K.; Saxena, N.; Chahdi, A.; Belo, A.; Khurana, S.; Xie, G. Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion of human colon cancer cells. Biochem. Biophys. Res. Commun. 2011, 415, 319-324.
12. Decock, J.; Paridaens, R.; Ye, S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin. Genet. 2008, 73, 197-211.
13. Leeman, M.F.; McKay, J.A.; Murray, G.I. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J. Clin. Pathol. 2002, 55, 758-762.
14. Huang, M.Y.; Chang, H.J.; Chung, F.Y.; Yang, M.J.; Yang, Y.H.; Wang, J.Y.; Lin, S.R. Mmp13 is a potential prognostic marker for colorectal cancer. Oncol. Rep. 2010, 24, 1241-1247.
15. Langenskiold, M.; Holmdahl, L.; Falk, P.; Ivarsson, M.L. Increased plasma mmp-2 protein expression in lymph node-positive patients with colorectal cancer. Int. J. Colorectal Dis. 2005, 20, 245-252.
16. Dragutinovic, V.V.; Radonjic, N.V.; Petronijevic, N.D.; Tatic, S.B.; Dimitrijevic, I.B.; Radovanovic, N.S.; Krivokapic, Z.V. Matrix metalloproteinase-2 (mmp-2) and -9 (mmp-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer. Mol. Cell. Biochem. 2011, 355, 173-178.
17. Kryczka, J.; Stasiak, M.; Dziki, L.; Mik, M.; Dziki, A.; Cierniewski, C. Matrix metalloproteinase-2 cleavage of the beta1 integrin ectodomain facilitates colon cancer cell motility. J. Biol. Chem. 2012, 287, 36556-36566.
18. Loesch, M.; Zhi, H.Y.; Hou, S.W.; Qi, X.M.; Li, R.S.; Basir, Z.; Iftner, T.; Cuenda, A.; Chen, G. P38gamma mapk cooperates with c-jun in trans-activating matrix metalloproteinase 9. J. Biol. Chem. 2010, 285, 15149-15158.
19. Papageorgis, P.; Cheng, K.; Ozturk, S.; Gong, Y.; Lambert, A.W.; Abdolmaleky, H.M.; Zhou, J.R.; Thiagalingam, S. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011, 71, 998-1008.
20. Zhang, B.; Halder, S.K.; Kashikar, N.D.; Cho, Y.J.; Datta, A.; Gorden, D.L.; Datta, P.K. Antimetastatic role of smad4 signaling in colorectal cancer. Gastroenterology 2010, 138, 969-980.
21. Garg, P.; Sarma, D.; Jeppsson, S.; Patel, N.R.; Gewirtz, A.T.; Merlin, D.; Sitaraman, S.V. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res. 2010, 70, 792-801.
22. Brabletz, T.; Jung, A.; Dag, S.; Hlubek, F.; Kirchner, T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 1999, 155, 1033-1038.
23. Maurel, J.; Nadal, C.; Garcia-Albeniz, X.; Gallego, R.; Carcereny, E.; Almendro, V.; Marmol, M.; Gallardo, E.; Maria Auge, J.; Longaron, R.; et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int. J. Cancer 2007, 121, 1066-1071.
24. Clapper, M.L.; Hensley, H.H.; Chang, W.C.; Devarajan, K.; Nguyen, M.T.; Cooper, H.S. Detection of colorectal adenomas using a bioactivatable probe specific for matrix metalloproteinase activity. Neoplasia 2011, 13, 685-691.
25. Ii, M.; Yamamoto, H.; Adachi, Y.; Maruyama, Y.; Shinomura, Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp. Biol. Med. 2006, 231, 20-27.
26. Adachi, Y.; Yamamoto, H.; Itoh, F.; Hinoda, Y.; Okada, Y.; Imai, K. Contribution of matrilysin (mmp-7) to the metastatic pathway of human colorectal cancers. Gut 1999, 45, 252-258.
27. Miyazaki, K.; Koshikawa, N.; Hasegawa, S.; Momiyama, N.; Nagashima, Y.; Moriyama, K.; Ichikawa, Y.; Ishikawa, T.; Mitsuhashi, M.; Shimada, H. Matrilysin as a target for chemotherapy for colon cancer: Use of antisense oligonucleotides as antimetastatic agents. Cancer Chemother. Pharmacol. 1999, 43, S52-S55.
28. Wilson, C.L.; Heppner, K.J.; Labosky, P.A.; Hogan, B.L.; Matrisian, L.M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA 1997, 94, 1402-1407.
29. Decock, J.; Thirkettle, S.; Wagstaff, L.; Edwards, D.R. Matrix metalloproteinases: Protective roles in cancer. J. Cell. Mol. Med. 2011, 15, 1254-1265.
30. Overall, C.M.; Kleifeld, O. Tumour microenvironment-opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227-239.
31. Asano, T.; Tada, M.; Cheng, S.; Takemoto, N.; Kuramae, T.; Abe, M.; Takahashi, O.; Miyamoto, M.; Hamada, J.; Moriuchi, T.; et al. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J. Surg. Res. 2008, 146, 32-42.
32. Shi, H.; Xu, J.M.; Hu, N.Z.; Wang, X.L.; Mei, Q.; Song, Y.L. Transfection of mouse macrophage metalloelastase gene into murine ct-26 colon cancer cells suppresses orthotopic tumor growth, angiogenesis and vascular endothelial growth factor expression. Cancer Lett. 2006, 233, 139-150.
33. Xu, Z.; Shi, H.; Li, Q.; Mei, Q.; Bao, J.; Shen, Y.; Xu, J. Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer. Oncol. Rep. 2008, 20, 81-88.
34. Yang, W.; Arii, S.; Gorrin-Rivas, M.J.; Mori, A.; Onodera, H.; Imamura, M. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 2001, 91, 1277-1283.
35. Bourboulia, D.; Stetler-Stevenson, W.G. Matrix met-aletal/et-alloproteinases (mmps) and tissue inhibitors of metalloproteinases (timps): Positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20, 161-168.
36. Kim, Y.S.; Ahn, Y.H.; Song, K.J.; Kang, J.G.; Lee, J.H.; Jeon, S.K.; Kim, H.C.; Yoo, J.S.; Ko, J.H. Overexpression and beta-1,6-n-acetylglucosaminylation-initiated aberrant glycosylation of timp-1: A -double whammy{norm of matrix} strategy in colon cancer progression. J. Biol. Chem. 2012, 287, 32467-32478.
37. Lee, J.H.; Choi, J.W.; Kim, Y.S. Plasma or serum timp-1 is a predictor of survival outcomes in colorectal cancer: A meta-analysis. J. Gastrointest. Liver Dis. 2011, 20, 287-291.
38. Holten-Andersen, M.N.; Christensen, I.J.; Nielsen, H.J.; Stephens, R.W.; Jensen, V.; Nielsen, O.H.; Sorensen, S.; Overgaard, J.; Lilja, H.; Harris, A.; et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin. Cancer Res. 2002, 8, 156-164.
39. Lu, K.V.; Jong, K.A.; Rajasekaran, A.K.; Cloughesy, T.F.; Mischel, P.S. Upregulation of tissue inhibitor of metalloproteinases (timp)-2 promotes matrix metalloproteinase (mmp)-2 activation and cell invasion in a human glioblastoma cell line. Lab. Investig. 2004, 84, 8-20.
40. Park, K.S.; Kim, S.J.; Kim, K.H.; Kim, J.C. Clinical characteristics of timp2, mmp2, and mmp9 gene polymorphisms in colorectal cancer. J. Gastroenterol. Hepatol. 2011, 26, 391-397.
41. Zhang, M.; Liu, Y.; Feng, H.; Bian, X.; Zhao, W.; Yang, Z.; Gu, B.; Li, Z. Cd133 affects the invasive ability of hct116 cells by regulating timp-2. Am. J. Pathol. 2013, 182, 565-576.
42. Powe, D.G.; Brough, J.L.; Carter, G.I.; Bailey, E.M.; Stetler-Stevenson, W.G.; Turner, D.R.; Hewitt, R.E. Timp-3 mrna expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br. J. Cancer 1997, 75, 1678-1683.
43. Lin, H.; Zhang, Y.; Wang, H.; Xu, D.; Meng, X.; Shao, Y.; Lin, C.; Ye, Y.; Qian, H.; Wang, S. Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells. Cancer Gene Ther. 2012, 19, 845-851.
44. Hilska, M.; Roberts, P.J.; Collan, Y.U.; Laine, V.J.; Kossi, J.; Hirsimaki, P.; Rahkonen, O.; Laato, M. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int. J. Cancer 2007, 121, 714-723.
45. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002, 295, 2387-2392.
46. Ogata, Y.; Matono, K.; Nakajima, M.; Sasatomi, T.; Mizobe, T.; Nagase, H.; Shirouzu, K. Efficacy of the mmp inhibitor mmi270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat. Int. J. Cancer 2006, 118, 215-221.
47. Roy, R.; Yang, J.; Moses, M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27, 5287-5297.
48. Hasegawa, S.; Koshikawa, N.; Momiyama, N.; Moriyama, K.; Ichikawa, Y.; Ishikawa, T.; Mitsuhashi, M.; Shimada, H.; Miyazaki, K. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer 1998, 76, 812-816.
49. Wu, J.; Wu, G.; Lv, L.; Ren, Y.F.; Zhang, X.J.; Xue, Y.F.; Li, G.; Lu, X.; Sun, Z.; Tang, K.F. Microrna-34a inhibits migration and invasion of colon cancer cells via targeting to fra-1. Carcinogenesis 2012, 33, 519-528.